- Investors & Media
- Investors & Media
- Contact Us
Kamada is a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, with a diverse portfolio of marketed products, a robust development pipeline and industry-leading manufacturing capabilities.
The company’s strategy is focused on driving profitable growth from current commercial activities as well as our manufacturing and development expertise in the plasma-derived biopharmaceutical market. The company’s commercial products portfolio includes its developed and FDA approved products GLASSIA® and KEDRAB® as well as its recently acquired FDA approved plasma-derived hyperimmune products CYTOGAM®, HEPAGAM B®, VARIZIG® and WINRHO®SDF. Kamada has additional four plasma-derived products which are registered in markets outside the U.S.
Kamada distributes its commercial products portfolio directly, and through strategic partners or third-party distributors in more than 30 countries, including the U.S., Canada, Israel, Russia, Brazil, Argentina, India and other countries in Latin America and Asia.
Kamada has a diverse portfolio of development pipeline products including an inhaled AAT for the treatment of AAT deficiency for which the company is currently conducting the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial.
Kamada leverages its expertise and presence in the Israeli pharmaceutical market to distribute in Israel more than 20 products that are manufactured by third parties and have recently added 11 biosimilar products to its Israeli distribution portfolio, which, subject to EMA and the Israeli MOH approvals, are expected to be launched in Israel between the years 2022 and 2028.
FIMI Opportunity Fund, the leading private equity investor in Israel, is the company’s lead shareholder, beneficially owning approximately 21% of the outstanding ordinary shares.
Founded in 1990, Kamada is listed on NASDAQ since 2013 and Tel-Aviv stock exchange since 2005 (KMDA).
Kamada’s headquarters is located in the Weizmann Science Park in Rehovot, Israel.